De geest en de letter

UNE PARTIE DE CAMPAGNE en LES BAS FONDS illustreren goed wat ik denk over het verband tussen scenario en de opnamen. Dat verband wordt gekenmerkt door een duidelijk gebrek aan trouw ...... 02 01 117 121

Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved

Besides demonstrated efficacy, selective serotonin reuptake inhibitors (SSRIs) hold other advantages over earlier antidepressants such as greater tolerability and a wider range of clinical applications. However, there is a growing body of clinical evidence which suggests that SSRIs could, in some cases, be associated with a withdrawal reaction upon cessation of regular use. In addition to sensory and gastrointestinal-related symptoms, the somatic symptoms of the SSRI discontinuation syndrome include dizziness, lethargy, and sleep disturbances. Psychological symptoms have also been documented, usually developing within 1–7 days following SSRI discontinuation. The characteristics of the discontinuation syndrome have been linked to the half-life of a given SSRI, with a greater number of reports emerging from paroxetine compared to other SSRIs. However, many aspects of the neurobiology of the SSRI discontinuation syndrome (or SSRI withdrawal syndrome) remain unresolved. Following a comprehensive overview of the clinical evidence, we will discuss the underlying pathophysiology of the SSRI discontinuation syndrome and comment on the use of animal models to better understand this condition

De akteur en de waarheid

Ik acht het onontbeerlijk voor een regisseur om enkele ontdekkingstochten te maken aan de andere kant van de kamera. Ik vergeet niet dat sommige van de grote regisseurs begonnen zijn als akteurs....... 02 01 122 125

Facilitating Financial Sustainability: Understanding the Drivers of CSO Financial Sustainability

Financial sustainability remains a critical challenge for Civil Society Organization (CSOs) around the world. Although a variety of toolkits and research papers exist examining specific sustainability strategies , many CSOs continue to struggle to develop and maintain the resources needed to carry out their missions. The Facilitating Financial Sustainability (FFS) activity was launched in 2017 to develop and test ways that different actors (including donors, policymakers, intermediary organizations, and CSOs themselves) can work together to improve the factors that drive financial sustainability for local organizations in different developing world contexts. This paper covers an analysis of the drivers of CSO sustainability based on interviews with CSO representatives. This represents one part of the three-part FFS research series, and is best considered alongside the other papers in the series to give a holistic perspective on CSO financial sustainability: "Funder Approaches to Facilitating CSO Financial Sustainability", which provides an overview of the funding landscape for financial sustainability in the six countries included in the study, and "Facilitating Financial Sustainability: Synthesis Report", which brings together the key findings from both other papers in the series

Estrogenic or antiestrogenic therapies for multiple myeloma?

Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and antiestrogenic compounds are very promising drugs for the treatment of MM. Indeed, they inhibit cell proliferation in vitro. They block cell cycle and/or induce apoptosis even in drug-resistant MM cells but not normal B cells. They interfere with survival pathways often deregulated in myelomas. They co-operate with conventional drugs to enhance apoptosis or to overcome resistance. In vivo, they act also on tumoral angiogenesis in xenograft models. As a whole, they possess all the criteria which render them attractive for a new therapeutic strategy. Importantly, they are well-tolerated at the doses tested in vitro or in vivo, encouraging the rapid onset of critical trials